secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001641172-25-016589
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine doses first patient in Phase 3 trial for oral brexanolone (LPCN 1154) in postpartum depression
--------------------------------------------------------------------------------

- First patient dosed in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression; top line data expected Q2 2026.
- Trial is outpatient with no medical monitoring required; 48-hour treatment regimen, randomized, blinded vs placebo in women ≥15 with severe PPD.
- Primary endpoint is change from baseline in HAM-D scale; NDA submission targeted for mid-2026 based on Phase 3 data.
- Virtual investor event on LPCN 1154 scheduled for July 9, 2025 at 11:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/0001641172-25-016589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer